Clinical Trial

Cardiovascular Effects of Angiotensin-(1-7) in Obesity Hypertension

Recruiting Early Phase 1
View on ClinicalTrials.gov →
Summary
Obesity is a global health concern that is associated with high blood pressure and an increased risk for developing cardiovascular disease. The purpose of this study is to find out if the investigational drug angiotensin-(1-7) can improve cardiovascular health in people with obesity and high blood pressure.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2024-06-26; most recent amendment 2025-09-18.
Trial Details
NCT Number NCT06482853
Lead Sponsor Milton S. Hershey Medical Center
Collaborators: National Heart, Lung, and Blood Institute (NHLBI)
Conditions Obesity, Hypertension
Enrollment 52 participants
Start Date 2025-01-23
Primary Completion 2029-03 (estimated)
Study Completion 2029-03 (estimated)
Updated on ClinicalTrials.gov 2025-09-19